Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/5/e003956.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850076063163482112 |
|---|---|
| author | Raffit Hassan Patrick M Forde Edward B Garon Steven M Dubinett Roy S Herbst Charu Aggarwal Matthew D Hellmann Sarah B Goldberg David L Rimm Sarah Sagorsky Boris Sepesi Ramaswamy Govindan Andrea Ferris Scott J Antonia Fred R Hirsch Lawrence H Schwartz Marianne Davies Melissa L Johnson Shakun Malik Daniel Morgensztern Joel W Neal Jyoti D Patel |
| author_facet | Raffit Hassan Patrick M Forde Edward B Garon Steven M Dubinett Roy S Herbst Charu Aggarwal Matthew D Hellmann Sarah B Goldberg David L Rimm Sarah Sagorsky Boris Sepesi Ramaswamy Govindan Andrea Ferris Scott J Antonia Fred R Hirsch Lawrence H Schwartz Marianne Davies Melissa L Johnson Shakun Malik Daniel Morgensztern Joel W Neal Jyoti D Patel |
| author_sort | Raffit Hassan |
| collection | DOAJ |
| description | Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or chemotherapy—have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma. |
| format | Article |
| id | doaj-art-a7041ff7bb174ceaaf1394ae132d1c32 |
| institution | DOAJ |
| issn | 2051-1426 |
| language | English |
| publishDate | 2022-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-a7041ff7bb174ceaaf1394ae132d1c322025-08-20T02:46:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-05-0110510.1136/jitc-2021-003956Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaRaffit Hassan0Patrick M Forde1Edward B Garon2Steven M Dubinett3Roy S Herbst4Charu Aggarwal5Matthew D Hellmann6Sarah B Goldberg7David L Rimm8Sarah Sagorsky9Boris Sepesi10Ramaswamy Govindan11Andrea Ferris12Scott J Antonia13Fred R Hirsch14Lawrence H Schwartz15Marianne Davies16Melissa L Johnson17Shakun Malik18Daniel Morgensztern19Joel W Neal20Jyoti D Patel21Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USAUpper Aerodigestive Division, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USADivision of Hematology/Oncology, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USADivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USASection of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USADivision of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USAMemorial Sloan Kettering Cancer Center, New York, New York, USASection of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USADepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut, USAUpper Aerodigestive Division, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USADepartment of Thoracic and Cardiovascular Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USALUNGevity Foundation, Chicago, Illinois, USADivision of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Cancer Immunotherapy, Durham, North Carolina, USACenter for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, New York, USADepartment of Radiology, Vagelos College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, USAYale School of Nursing, Yale Cancer Center, New Haven, Connecticut, USASarah Cannon Research Institute, Nashville, Tennessee, USADivision of Cancer Treatment & Diagnosis, CTEP, National Cancer Institute, Rockville, Maryland, USADepartment of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USAStanford Cancer Institute, Stanford University, Stanford, California, USARobert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USAImmunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or chemotherapy—have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma.https://jitc.bmj.com/content/10/5/e003956.full |
| spellingShingle | Raffit Hassan Patrick M Forde Edward B Garon Steven M Dubinett Roy S Herbst Charu Aggarwal Matthew D Hellmann Sarah B Goldberg David L Rimm Sarah Sagorsky Boris Sepesi Ramaswamy Govindan Andrea Ferris Scott J Antonia Fred R Hirsch Lawrence H Schwartz Marianne Davies Melissa L Johnson Shakun Malik Daniel Morgensztern Joel W Neal Jyoti D Patel Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma Journal for ImmunoTherapy of Cancer |
| title | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
| title_full | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
| title_fullStr | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
| title_full_unstemmed | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
| title_short | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
| title_sort | society for immunotherapy of cancer sitc clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
| url | https://jitc.bmj.com/content/10/5/e003956.full |
| work_keys_str_mv | AT raffithassan societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT patrickmforde societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT edwardbgaron societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT stevenmdubinett societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT roysherbst societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT charuaggarwal societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT matthewdhellmann societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT sarahbgoldberg societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT davidlrimm societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT sarahsagorsky societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT borissepesi societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT ramaswamygovindan societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT andreaferris societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT scottjantonia societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT fredrhirsch societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT lawrencehschwartz societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT mariannedavies societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT melissaljohnson societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT shakunmalik societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT danielmorgensztern societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT joelwneal societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma AT jyotidpatel societyforimmunotherapyofcancersitcclinicalpracticeguidelineonimmunotherapyforthetreatmentoflungcancerandmesothelioma |